HB Wealth Management
ELTX icon

HB Wealth Management’s Elicio Therapeutics ELTX Stock Holding History

HB Wealth Management’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$45.7K Buy
25,118
+14,655
+140% +$40.7K ﹤0.01% 1843
2026
Q2 		$40.9K Hold
10,463
– – ﹤0.01% 1685
2026
Q1 		$112K Buy
+10,463
New +$101K ﹤0.01% 1492

Other funds holding ELTX

Shah Capital Management
Shah Capital Management Raleigh, North Carolina $605M AUM 43.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Leonteq Securities AG
Leonteq Securities AG Zurich, Switzerland $2.44B AUM 50.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Meyer Handelman Company
Meyer Handelman Company Rye Brook, New York $3.49B AUM 26.82% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Abel Hall LLC
Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return
Moody Lynn & Lieberson
Moody Lynn & Lieberson Boston, Massachusetts $1.93B AUM 20.85% 1-Year Est. Return

HB Wealth Management's ELTX Position: Q3 2026 in Review

HB Wealth Management increased its Elicio Therapeutics (ELTX) stake by 140% in Q3 2026, buying an estimated $40.7K and bringing the position to 25,118 shares worth $45.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1843.

HB Wealth Management first reported a position in ELTX in Q1 2026 and has held it in 3 quarters since. The position peaked at $112K in Q1 2026. 27 funds tracked by Wall St. Rank hold ELTX as of Q3 2026.

  • HB Wealth Management held 25,118 shares of Elicio Therapeutics worth $45.7K as of Q3 2026.
  • HB Wealth Management bought 14,655 Elicio Therapeutics shares in Q3 2026, an estimated $40.7K.
  • Elicio Therapeutics made up ﹤0.01% of HB Wealth Management's portfolio in Q3 2026, its #1843 holding.
  • HB Wealth Management first reported a position in Elicio Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • HB Wealth Management's Elicio Therapeutics position peaked at $112K in Q1 2026.
  • 27 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q3 2026.

Based on HB Wealth Management's 13F filing for Q3 2026, filed 23 Oct 2026.